Addiction professionals, lawmakers announce NC treatment connection campaign
RALEIGH, N.C. (WNCN) — There is a new campaign to help those battling addiction receive proper care.
Wednesday, Addiction Professionals of North Carolina (APNC) and several state lawmakers announced the launch of NC Treatment Connection.
The new campaign is developed from the passage of the Stop Addiction Fraud Ethics Act, also known as the S.A.F.E Act of 2023.
'That made patient brokering a Class G felony, it made it illegal; however, not everybody knows what I mean when I say patient brokering and that's the point of this campaign,' said Sara Howe, CEO of APNC
Howe says patient brokering occurs more often than you think and that's why this law was passed.
'What will happen is that bad actors will show up at an AA meeting, an NA meeting, they will befriend somebody and then they will help them to relapse, and then provide them what they believe is a treatment center that they will send them to,' said Howe. 'Often the patient broker will get a kickback for that, they will get a bounty for that person, but the treatment center isn't a good quality, ethical treatment center.'
She and others say this new campaign will help those facing addiction find trusted resources.
'Substance abuse disorders are a crisis. It claims the lives of 12 North Carolinians every day,' said Rep. Timothy Reeder. 'It costs $6.8 billion annually with healthcare costs, and this impact is the cost but the devastation on the families is really what we worry about.'
APNC Outreach Director, Michael Roberts says a campaign like this is needed.
He's been sober for nine years.
'I'm alive because there's programs that exist to help people like me, programs that didn't pay me to relapse,' said Roberts. 'We're making people know so that when someone reached out for help they get the right kind.'
You can find more information on the NC Treatment Connection here
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
NC doctors, legislators, and cancer survivors push for prostate cancer screening money
New Bern Alderman Victor Taylor speaks about his prostate cancer treatment at a news conference on a proposal to establish a statewide screening program for uninsured and underinsured men. (Photo: Lynn Bonner/NC Newsline) Offering prostate cancer screening to men who are uninsured or underinsured will save lives, legislators, doctors, advocates, and cancer survivors said at a news conference Tuesday. 'Prostate cancer is one of the most curable cancers if it is detected early,' said Rep. Rodney Pierce (D-Halifax), the bill's lead sponsor. But, too many North Carolinians are diagnosed too late. 'This legislation is about saving lives, about a higher quality of life, and giving our fathers, uncles, brothers, nephews and sons the fighting chance they deserve,' he said. House bill 128 would appropriate $2 million to establish a prostate cancer screening program modeled after the state's breast and cervical cancer screening program. Money for prostate screening is not in the House or Senate budget proposals, but Pierce hopes it will be funded. Prostate cancer is the second leading cause of cancer deaths among men in the state, according to the UNC Men's Health Program. The issue has gained increased attention in the last few weeks after former President Joe Biden was diagnosed with 'a more aggressive form' of prostate cancer. Men in North Carolina are diagnosed with prostate cancer at higher rates than men nationally, according to the National Cancer Institute, and North Carolina's mortality rate is higher, at 20.2 per 100,000 men. Black men are more likely to develop prostate cancer and more likely to die from it, according to the American Cancer Society. Legislators at the Tuesday news conference made direct appeals to Black men to be screened. A blood test is used to screen for and monitor prostate cancer. Rep. Abe Jones (D-Wake) said he's tested twice a year because his father had prostate cancer. 'It is a sneaky, nasty, tricky disease,' Jones said. 'It's ugly and it kills Black men at a higher rate.' 'It doesn't give you a warning, it just comes on you,' Jones said. 'I just encourage all my brothers out there to please get tested.' New Bern Alderman Victor Taylor, a prostate cancer survivor, said the screening bill would help men in rural areas. It's vital for men to talk about prostate cancer, he said. 'It's so important to talk, talk, talk and share,' he said. 'You don't know how many lives you've saved by talking and sharing.' The bill proposes free or low-cost testing for uninsured or underinsured men ages 40 to 70 who have a family history of prostate cancer. Men without a family history would be eligible for screening at ages 50 to 70. Recommendations for screening have a cloudy history. In 2012, the US Preventative Service Task Force, a group of independent experts, recommended against routine screening. The recommendation changed in 2018, with the group suggesting men 55- to 69-years old talk with their doctors about regular screening. The task force is in the process of updating its recommendation. Dr. Dan George, a member of the Duke Cancer Institute who specializes in prostate cancers, said there's a concern that prostate cancer is going under-treated. 'It's so vitally important for people to recognize that knowledge is power,' George said. 'Understanding your cancer status is an opportunity for you to prevent a leading cause of death in this state.' Rural residents would benefit from routine testing that residents with access to medical specialists can more easily obtain, he said. Former state Sen. Eddie Goodall, a Union County Republican, talked about his prostate cancer diagnosis and treatment. Goodall said he was diagnosed in 2005, just as his first term in the legislature was beginning. 'I was excited about being a freshman senator and being able to change the world,' Goodall said. Instead, he received a diagnosis that he kept secret from his mother because he didn't want her to worry about another son dying. Goodall said that five years before he was diagnosed, his brother died of cancer. Goodall said he talked and compared notes with another former senator who was diagnosed with prostate cancer at about the same time. Goodall decided against surgery. The cancer spread to his bones. Goodall said he started hormone therapy in 2018 and was told he had 18 months to two years to live. 'But it's been seven years, and I'm still here. So I'm very grateful for that.'
Yahoo
2 days ago
- Yahoo
Coverage of weight-loss drugs should be a no-brainer for state's Medicaid program
Packages of the injectable weight-loss medication Wegovy are shown (Photo illustration by) If North Carolinians lived in a perfect world, everyone would have easy access to plenty of healthy and affordable food, the self-control to resist junk food, and genes that would let them stay active, trim and fit throughout their lives. Unfortunately, we don't live in such a world. And it's in light of this that it was a no-brainer for state Health and Human Services officials to make prescriptions for weight-loss drugs a covered expense under the state Medicaid program. As Jonathan Ray – a Charlotte physician assistant – wrote in a recent essay for NC Newsline, these medicines have helped thousands upon thousands of people to achieve significant weight loss, improve their metabolic health, and reduce the risk of chronic diseases like diabetes and heart disease. Unfortunately, recent actions by state legislative leaders could end the funding for these essential medications. The bottom line: In the imperfect world we inhabit, weight-loss drugs save health, lives and money. It would be cruel and foolish to end Medicaid coverage for these essential medicines. For NC Newsline, I'm Rob Schofield.
Miami Herald
3 days ago
- Miami Herald
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025 Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo, CEO of Arby's, and as an early-stage investor/board member in healthcare and software businesses HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors has elected Michael C. Howe, as the Company's new chief executive officer. The Board selected Michael Howe to be CEO based on his proven track record of hands-on success during his more than four decades of experience with leading brands and early-stage companies, and his recognized leadership qualities. Kraig Higginson, who has stepped down as CEO and Chairman of the Board, will remain with the Company and serve as Executive Chairman of the Board. Michael Howe is a visionary C-level executive with a proven record of driving transformative success across diverse industries. With a deep understanding of market trends, consumer behavior, and innovative brand positioning, Howe has consistently demonstrated his ability to foresee and shape consumer trends, leading to the creation of groundbreaking operational strategies. His career has been marked by his ability to build and strengthen nationally recognized brands with companies such as MinuteClinic, Procter & Gamble, PepsiCo and Arby's. His strategic leadership has consistently delivered significant growth and financial success, from start-ups to multinational corporations. His healthcare leadership and expertise in creating innovative consumer focused brands was most effectively demonstrated in his leadership of MinuteClinic, a network of board-certified health providers offering high-quality, team-based care services. Howe joined MinuteClinic in June 2005 with 19 clinics in two markets as the brand struggled to define a clear national expansion strategy. Within 15 months, Howe added more than 100 clinics in 13 markets and facilitated the sale of the company to CVS in September 2006, which delivered a nearly sixfold return for investors. He stayed with CVS as CEO of MinuteClinic for 2 additional years leading the national expansion to more than 530 clinics. Since 2022, Howe has served as a Co-founder and CEO of The Good Clinic (TGC), which offered a holistic care approach to primary healthcare services, integrating functional medicine, genetic testing, technology, alternative treatments, and nutrition. Howe is now leading the funding and expansion to relaunch the TGC concept under the newly formed First Choice Healthcare Solutions. Since 2021, he has also served as an independent director for P1 Dental Partners, an Indianapolis-based, PE-funded dental services organization. "Michael is a seasoned strategist with a track record of driving sustainable growth through innovation, and we have every confidence in his ability to lead Aspire during this important time," said Kraig Higginson, Executive Chairman of Aspire. "He brings meaningful expertise in scaling differentiated platforms and has a deep understanding of the health and wellness sector - making him uniquely suited to serve as Aspire's next CEO. I have worked closely with Michael over the past six months as a fellow board member during which time his contributions and insights have confirmed the excellent qualities he brings to the role. Together with the entire Board, I look forward to working with him." On his appointment, Howe said, "I am honored to be named as CEO of Aspire. I am grateful to our Executive Chairman, Kraig Higginson for his commitment, leadership and passion, and to the members of our Board for their leadership, particularly in these recent months, and for the confidence they have placed in me to lead our business." Howe continued "Aspire has a powerful and differentiated drug delivery platform, is engaged in an important clinical trial which could support a submission to the FDA via the 505(b)(2) pathway, and has the opportunity to generate early revenue upon the launch of its novel pre-workout supplement, both of which are expected to occur in 2025. I am eager to build upon the work the entire Aspire team has been doing to position our business for the future and create value for our shareholders over the long-term." Higginson added, "It has been a privilege to lead Aspire. I am proud of what we have accomplished, and I want to express my thanks to the many team members who, through their hard work and commitment to the company, have made our success possible. From the going public process, to commencing the first FDA clinical trials of our high-dose aspirin, to preparing for the launch of our innovative pre-workout product, BUZZ BOMB™, now is the right time to transition the leadership of Aspire to Michael. I believe the Company and shareholders will benefit from his experience as a strategic thinker with a laser focus on capturing current market and operational opportunities." About Michael C. Howe A successful growth-oriented CEO with 40+ years of consumer and healthcare experience. Howe has established a proven track record of leading and building successful consumer focused businesses across several different business sectors including consumer goods, fast food restaurants, SaaS products, and innovative healthcare companies. He began his career at Procter & Gamble with positions in sales and marketing. He then joined PepsiCo in their fast-food division with operational roles with the KFC brand. Five years later, he joined Arby's as a senior operational executive, subsequently rising to the position of President and CEO, growing the brand's revenue by 25% in just 3 years. After a successful term as CEO of Arby's, Howe joined MinuteClinic in June 2005 and within 15 months orchestrated the sale of the company to CVS in September 2006, where he remained for 2 additional years leading the national expansion. After leaving CVS in 2008, he founded Howe & Associates, which focused on supporting start up and early- stage companies in their expansion processes, as an angel investor, board member, and / or executive, leading 11 companies to a successful financial exit. Howe earned both his accounting and business degrees from the University of Minnesota, Duluth after serving 4 years in the U.S. Air Force. About the Aspire Targeted Oral Delivery Platform Aspire's sublingual delivery technology has been developed using our patent-pending methodology, and "trade secret" process. The technology's new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream of supplements and other substances. The benefits of "rapid absorption" are to provide rapid impact in more precise quantities. About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which can deliver supplements and drugs rapidly and precisely. For more information, please visit Safe Harbor Statement Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Aspire Biopharma Holdings, Inc. ContactTraDigital IRKevin McGrath+1-646-418-7002kevin@ SOURCE: Aspire Biopharma Holdings, Inc.
